Inhibition of drug efflux in mycobacteria with phenothiazines and other putative efflux inhibitors

Recent Patents on Anti-Infective Drug Discovery

Volumn 6, Issue 2, 2011, Pages 118-127

  Rodrigues, Liliana ^a   Aínsa, José A ^b,c   Amaral, Leonard ^a,c   Viveiros, Miguel ^a,c  

^a INSTITUTO DE HIGIENE E MEDICINA TROPICAL   (Portugal)

^b UNIVERSITY OF ZARAGOZA   (Spain)

^c COST Action ^*  (Portugal)

Author keywords

Efflux inhibitors; Efflux pumps; Mycobacteria; Phenothiazines; Thioridazine; Tuberculosis

Indexed keywords

ANTIMYCOBACTERIAL AGENT; BIOCHANIN A; CHLORPROMAZINE; FARNESOL; LUTEOLIN; PHENOTHIAZINE DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RESERPINE; RIFAMPICIN; TETRACYCLINE; THIORIDAZINE; UNCLASSIFIED DRUG; VERAPAMIL; WO 2004062647; WO 2008141012; WO 2009110002; WO 2010054102;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENE; BACTERIUM ISOLATE; DRUG EFFICACY; DRUG MECHANISM; DRUG PENETRATION; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; DRUG TRANSPORT; DRUG USE; MEMBRANE PERMEABILITY; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM; MYCOBACTERIUM AVIUM; MYCOBACTERIUM SMEGMATIS; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTITUBERCULAR AGENTS; BACTERIAL PROTEINS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG THERAPY, COMBINATION; HUMANS; ION TRANSPORT; KINETICS; MEMBRANE TRANSPORT MODULATORS; MEMBRANE TRANSPORT PROTEINS; MYCOBACTERIUM TUBERCULOSIS; PHENOTHIAZINES; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 79960065506     PISSN: 1574891X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489111796064579     Document Type: Article

References (71)

1. World Health Organization (WHO). Global tuberculosis control report. WHO: Geneva 2010.
2. Griffith DE. Therapy of nontuberculous mycobacterial disease. Curr Opin Infect Dis 2007; 20: 198-203.
3. Somoskovi A, Parsons LM, Salfinger M. The molecular basis of resistance to isoniazid, rifampin, and pyrazinamide in Mycobacterium tuberculosis. Respir Res 2001; 2: 164-8.
4. Wayne LG. Dormancy of Mycobacterium tuberculosis and latency of disease. Eur J Clin Microbiol Infect Dis 1994; 13: 908-14.
5. Elliott AM, Berning SE, Iseman MD, Peloquin CA. Failure of drug penetration and acquisition of drug resistance in chronic tuberculous empyema. Tuber Lung Dis 1995; 76: 463-7.
6. Nikaido H. Multidrug resistance in bacteria. Annu Rev Biochem 2009; 78: 119-46.
7. Davin-Regli A, Bolla JM, James CE, Lavigne JP, Chevalier J, Garnotel E, et al. Membrane permeability and regulation of drug influx and efflux in enterobacterial pathogens. Curr Drug Targets 2008; 9: 750-9.
8. Viveiros M, Dupont M, Rodrigues L, Couto I, Davin-Regli A, Pagès JM, et al. Antibiotic stress, genetic response and altered permeability of E. coli. PLoS ONE 2007; 2: e365.
9. Pagès JM, Amaral L. Mechanisms of drug efflux and strategies to combat them: Challenging the efflux pump of Gram-negative bacteria. Biochim Biophys Acta 2009; 1794: 826-33.
10. Piddock LJ. Clinically relevant chromosomally encoded multidrug resistance efflux pumps in bacteria. Clin Microbiol Rev 2006; 19: 382-402.
11. Quinn T, O'Mahony R, Baird AW, Drudy D, Whyte P, Fanning S. Multi-drug resistance in Salmonella enterica: Efflux mechanisms and their relationships with the development of chromosomal resistance gene clusters. Curr Drug Targets 2006; 7: 849-60.
12. Baucheron S, Tyler S, Boyd D, Mulvey MR, Chaslus-Dancla E, Cloeckaert A. AcrAB-TolC directs efflux-mediated multidrug resistance in Salmonella enterica serovar Typhimurium DT104. Antimicrob Agents Chemother 2004; 48: 3729-35.
13. Hancock RE, Speert DP. Antibiotic resistance in Pseudomonas aeruginosa: Mechanisms and impact on treatment. Drug Resist Updat. 2000; 3: 247-55.
14. Brennan PJ, Nikaido H. The envelope of mycobacteria. Annu Rev Biochem 1995; 64: 29-63.
15. Draper P. The outer parts of the mycobacterial envelope as permeability barriers. Front Biosci 1998; 3: 1253-61.
16. Lambert PA. Cellular impermeability and uptake of biocides and antibiotics in gram-positive bacteria and mycobacteria. Symp Ser Soc Appl Microbiol 2002; 31: 46S-54S.
17. Niederweis M. Nutrient acquisition by mycobacteria. Microbiology 2008; 154: 679-92.
18. Niederweis M, Danilchanka O, Huff J, Hoffmann C, Engelhardt H. Mycobacterial outer membranes: In search of proteins. Trends Microbiol 2010; 18: 109-16.
19. Trias J, Jarlier V, Benz R. Porins in the cell wall of mycobacteria. Science 1992; 258: 1479-81.
20. De Rossi E, Aínsa JA, Riccardi G. Role of mycobacterial efflux transporters in drug resistance: An unresolved question. FEMS Microbiol Rev 2006; 30: 36-52.
21. Louw GE, Warren RM, van Pittius NC, McEvoy CR, Van Helden PD, Victor TC. A balancing act: Efflux/influx in mycobacterial drug resistance. Antimicrob Agents Chemother 2009; 53: 3181-9.
22. Viveiros M, Leandro C, Amaral L. Mycobacterial efflux pumps and chemotherapeutic implications. Int J Antimicrob Agents 2003; 22: 274-8.
23. Ramon-Garcia S, Martín C, Thompson CJ, Aínsa JA. Role of the Mycobacterium tuberculosis P55 efflux pump in intrinsic drug resistance, oxidative stress responses, and growth. Antimicrob Agents Chemother 2009; 53: 3675-82.
24. Takiff HE, Cimino M, Musso MC, Weisbrod T, Martinez R, Delgado MB, et al. Efflux pump of the proton antiporter family confers low-level fluoroquinolone resistance in Mycobacterium smegmatis. Proc Natl Acad Sci USA 1996; 93: 362-6.
25. Sander P, De Rossi E, Böddinghaus B, Cantoni R, Branzoni M, Böttger EC, et al. Contribution of the multidrug efflux pump LfrA to innate mycobacterial drug resistance. FEMS Microbiol. Lett 2000; 193: 19-23.
26. Alland D, Steyn AJ, Weisbrod T, Aldrich K, Jacobs WR Jr. Characterization of the Mycobacterium tuberculosis iniBAC promoter, a promoter that responds to cell wall biosynthesis inhibition. J Bacteriol 2000; 182: 1802-11.
27. Camacho LR, Constant P, Raynaud C, Laneelle MA, Triccas JA, Gicquel B, et al. Analysis of the phthiocerol dimycocerosate locus of Mycobacterium tuberculosis. Evidence that this lipid is involved in the cell wall permeability barrier. J Biol Chem 2001; 276: 19845-54.
28. Gupta AK, Reddy VP, Lavania M, Chauhan DS, Venkatesan K, Sharma VD, et al. jefA (Rv2459), a drug efflux gene in Mycobacterium tuberculosis confers resistance to isoniazid & ethambutol. Indian J Med Res. 2010; 132: 176-88.
29. Daigle DM, McKay GA, Wright GD. Inhibition of aminoglycoside antibiotic resistance enzymes by protein kinase inhibitors. J Biol Chem 1997; 272: 24755-8.
30. Martins M, Dastidar SG, Fanning S, Kristiansen JE, Molnar J, Pagès JM, et al. Potential role of non-antibiotics (helper compounds) in the treatment of multidrug-resistant Gram-negative infections: Mechanisms for their direct and indirect activities. Int J Antimicrob Agents 2008; 31: 198-208.
31. Lomovskaya O, Watkins W. Inhibition of efflux pumps as a novel approach to combat drug resistance in bacteria. J Mol Microbiol Biotechnol 2001; 3: 225-36.
32. Lomovskaya O, Zgurskaya HI, Totrov M, Watkins WJ. Waltzing transporters and 'the dance macabre' between humans and bacteria. Nat Rev Drug Discov 2007; 6: 56-65.
33. Watkins WJ, Chong L, Cho A, Hilgenkamp R, Ludwikow M, Garizi N, et al. Quinazolinone fungal efflux pump inhibitors. Part 3: (N-methyl)piperazine variants and pharmacokinetic optimization. Bioorg Med Chem Lett 2007; 17: 2802-6.
34. Nelson, M.L., Alekshun, M.N. Substituted polyamines as inhibitors of bacterial efflux pumps. WO2004062674 (2004).
35. Glinka, T., Rodny, O., Bostian, K., Wallace, D.M. Quaternary alkyl ammonium bacterial efflux pump inhibitors and therapeutic uses thereof. WO2008141012 (2008).
36. Koul, S., Thota, N., Mallepally, V.R., Sangwan, P.L., Taneja, S.C., Khan, I.A., Kumar, A., Raja, A.F., Saxena, A.K., Agrawal, S.K., Johri, R.K., Abdullah, S.T., Singh, G., Bachu, L.N.R., Dhar, A.K., Purnima, B., Qazi, G.N. Novel efflux pump inhibitors. WO2009110002 (2009).
37. Glinka, T., Rodny, O., Bostian, K.A., Wallace, D.M., Higuchi, R., Chow, C., Mak, C.C., Hirst, G., Eastman, B. Polybasic bacterial efflux pump inhibitors and therapeutic uses thereof. WO2010054102 (2010).
38. Krulwich TA, Quirk PG, Guffanti AA. Uncoupler-resistant mutants of bacteria. Microbiol Rev 1990; 54: 52-65.
39. Marquez B. Bacterial efflux systems and efflux pumps inhibitors. Biochimie 2005; 87: 1137-47.
40. Stavri M, Piddock LJ, Gibbons S. Bacterial efflux pump inhibitors from natural sources. J Antimicrob Chemother 2007; 59: 1247-60.
41. Markham PN, Neyfakh A. Inhibition of the multidrug transporter NorA prevents emergence of norfloxacin resistance in Staphylococcus aureus. Antimicrob Agents Chemother 1996; 40: 2673-4.
42. Viveiros M, Portugal I, Bettencourt R, Victor TC, Jordaan AM, Leandro C, et al. Isoniazid-induced transient high-level resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2002; 46: 2804-10.
43. Pasca MR, Guglierame P, Arcesi F, Bellinzoni M, De Rossi E, Riccardi G. Rv2686c-Rv2687c-Rv2688c, an ABC fluoroquinolone efflux pump in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2004; 48: 3175-8.
44. Rodrigues L, Wagner D, Viveiros M, Sampaio D, Couto I, Vavra M, et al. Thioridazine and chlorpromazine inhibition of ethidium bromide efflux in Mycobacterium avium and Mycobacterium smegmatis. J Antimicrob Chemother 2008; 61: 1076-82.
45. Rodrigues L, Sampaio D, Couto I, Machado D, Kern WV, Amaral L, et al. The role of efflux pumps in macrolide resistance in Mycobacterium avium complex. Int J Antimicrob Agents 2009; 34: 529-33.
46. Lechner D, Gibbons S, Bucar F. Plant phenolic compounds as ethidium bromide efflux inhibitors in Mycobacterium smegmatis. J Antimicrob Chemother 2008; 62: 345-8.
47. Sharma S, Kumar M, Sharma S, Nargotra A, Koul S, Khan IA. Piperine as an inhibitor of Rv1258c, a putative multidrug efflux pump of Mycobacterium tuberculosis. J Antimicrob Chemother 2010; 65: 1694-701.
48. Jin J, Zhang JY, Guo N, Sheng H, Li L, Liang JC, et al. Farnesol, a potential efflux pump inhibitor in Mycobacterium smegmatis. Molecules 2010; 15: 7750-62.
49. Ehrlich P. The Collected Papers of Paul Ehrlich. Himmelweit F, Marquardi M, Dale H (Eds). Pergammon Press: London 1956.
50. Viveiros M, Amaral L. Enhancement of antibiotic activity against poly-drug resistant Mycobacterium tuberculosis by phenothiazines. Int J Antimicrob Agents 2001; 17: 225-8.
51. Amaral L, Kristiansen JE, Abebe LS, Millett W. Inhibition of the respiration of multi-drug resistant clinical isolates of Mycobacterium tuberculosis by thioridazine: Potential use for initial therapy of freshly diagnosed tuberculosis. J Antimicrob Chemother 1996; 38: 1049-53.
52. Amaral L, Viveiros M, Molnar J. Antimicrobial activity of phenothiazines. In Vivo 2004; 18: 725-32.
53. Crowle AJ, Douvas GS, May MH. Chlorpromazine: A drug potentially useful for treating mycobacterial infections. Chemotherapy 1992; 38: 410-19.
54. Ordway D, Viveiros M, Leandro C, Amaral L. Clinical concentrations of thioridazine kill intracellular multi-drug resistant Mycobacterium tuberculosis. Antimicrob. Agents Chemother 2003; 47: 917-22
55. Martins M, Viveiros M, Kristiansen JE, Molnar J, Amaral L. The curative activity of thioridazine on mice infected with Mycobacterium tuberculosis. In Vivo 2007; 21: 771-5.
56. Amaral L, Martins M, Viveiros M. Phenothiazines as anti-multidrug resistant tubercular agents. Infect. Disord. Drug Targets 2007; 7: 257-65.
57. Dutta NK, Mehra S, Kaushal D. A Mycobacterium tuberculosis sigma factor network responds to cell-envelope damage by the promising anti-mycobacterial thioridazine. PLoS One 2010; 5(4): e10069. doi:10.1371/journal.pone.0010069.
58. Weiss B, Prozialeck W, Cimino M, Barnette MS, Wallace TL. Pharmacological regulation of calmodulin. Ann NY Acad Sci 1980; 356: 319-45.
59. Garcia JJ, Tuena de Gomez-Puyou M, Gomez-Puyou A. Inhibition by trifluoperazine of ATP synthesis and hydrolysis by particulate and soluble mitochondrial F1: Competition with H2PO4. J Bioenerg Biomembr 1995; 27: 127-36.
60. Kristiansen MM, Leandro C, Ordway D, Martins M, Viveiros M, Pacheco T, et al. Phenothiazines alter resistance of methicillin resistant strains of Staphylococcus aureus (MRSA) to oxacillin in vitro. Int J Antimicrob Agents 2003; 22: 250-3.
61. Bhatnagar K, Singh VP. Ca2+-dependence and inhibition of transformation by trifluoperazine and chlorpromazine in Thermoactinomyces vulgaris. Curr Microbiol 2003; 46: 265-9.
62. Wittekindt OH, Schmitz A, Lehmann-Horn F, Hansel W, Grissmer S. The human Ca2+-activated K+ channel, IK, can be blocked by the tricyclic antihistamine promethazine. Neuropharmacology 2006; 50: 458-67.
63. Ahluwalia J, Tinker A, Clapp LH, Duchen MR, Abramov AY, Pope S, et al. The large-conductance Ca2+-activated K+ channel is essential for innate immunity. Nature 2004; 427: 853-8.
64. Boshoff HI., Myers TG, Copp BR, McNeil MR, Wilson MA,. Barry CE III. The transcriptional responses of Mycobacterium tuberculosis to inhibitors of metabolism: novel insights into drug mechanisms of action. J Biol Chem 2004: 279: 40174-84.
65. Viveiros M, Martins A, Paixão L, Rodrigues L, Martins M, Couto I, et al. Demonstration of intrinsic efflux activity of Escherichia coli K-12 AG100 by an automated ethidium bromide method. Int J Antimicrob Agents 2008; 31: 458-62.
66. Aínsa JA, Blokpoel MC, Otal I, Young DB, De Smet KA, Martín C. Molecular cloning and characterization of Tap, a putative multidrug efflux pump present in Mycobacterium fortuitum and Mycobacterium tuberculosis. J Bacteriol 1998; 180: 5836-43.
67. Ramon-Garcia S, Martín C, Aínsa JA, De Rossi E. Characterization of tetracycline resistance mediated by the efflux pump Tap from Mycobacterium fortuitum. J Antimicrob Chemother 2006; 57: 252- 259.
68. Hurdle JG, O'Neill AJ, Chopra I, Lee RE. Targeting bacterial membrane function: An underxploited mechanism for treating persistent infections. Nat Rev Microbiol 2011; 9: 62-75.
69. Abbate E, Vescoso M, Natiello M, Cufre M, Garcia A, Ambroggi M, et al. Tuberculosis extensamente resistente (XDR-TB) en Argentina: aspectos destacbles epidemiologicos, bacteriologicos, terapeuticos y evolutivos. Revista Argentina de Medicina Respiratoria 2007; 1: 19-25.
70. Amaral L, Boeree MJ, Gillespie SH, Udwadiad ZF, van Soolingen D. Thioridazine cures extensively drug-resistant tuberculosis (XDR-TB) and the need for global trials is now! Int J Antimicrob Agents 2010; 35: 524-6.
71. Clinical and Laboratory Standards Institute (CLSI). Susceptibility testing of mycobacteria, nocardia and other aerobic actinomycetes; Approved standard; M24-A. CLSI: Wayne, PA 2003; 23(18).